Seeking Alpha

OncoGenex gets a lift from Needham

  • OncoGenex Pharmaceuticals (OGXI) jumps 10% before the bell.
  • Needham's Chad Messer says that "while Xtandi and other prostate cancer agents in development may eventually erode chemotherapy use in prostate cancer, this concern is nothing new and [may not] have a material effect on the long-term value" of the shares.
  • OGXI upgraded to Strong Buy. Price target lifted to $30 (from $20) — so Messer is essentially looking for the shares to quadruple.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs